MedPath

Hybrid PET/CT in Cancer Patients

Not Applicable
Completed
Conditions
Cancer
Registration Number
NCT00396916
Lead Sponsor
Rambam Health Care Campus
Brief Summary

The purpose of the present study is to assess the role of hybrid PET/CT imaging diagnosis of active malignancy in cancer patients with rising tumor markers after treatment and in the diagnosis of primary tumor in patients with metastatic cancer of unknown origin. The clinical impact of PET/CT in the management and treatment of these two groups of cancer patients will be evaluated

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
45
Inclusion Criteria
  • Cancer patients in complete remission after treatment, with serial elevation of serum tumor markers and negative CT or other conventional imaging test.
  • Patients with newly diagnosed metastatic cancer with unknown primary tumor
  • Glucose levels below 150-200
  • Patient signed informed consent
Exclusion Criteria
  • Pregnant or lactating women
  • Patient unable or not willing to tolerate the test until its completion
  • One or more of the inclusion criteria is not fulfilled

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
the impact of the imaging modality on patient management
Secondary Outcome Measures
NameTimeMethod
the impact of the imaging modality on patient management

Trial Locations

Locations (1)

Rambam Medical Center

🇮🇱

Haifa, Israel

© Copyright 2025. All Rights Reserved by MedPath